1月7日早间，英集芯公告称， 其IPA1299芯片系与参股公司精芯唯尔（常州）电子科技有限公司共同 推出，是一款支持8通道低噪声设计，24位同步采样模数转换器芯片（ADC），主要应用于脑电图 （EEG）、心电图（ECG）和肌电图（EMG），该产品主要特点在于可实现高精度信号采集功能，可 应用于非侵入式脑机接口领域。 2月13日，证监会公告，2026年1月6日，深圳英集芯科技股份有限公司（简称英集芯）在上证E互动 平台人为策划"自问自答"，信息披露构成误导性陈述。近日，证监会已对英集芯立案调查。 下一步，证监会将在全面调查的基础上依法处理，切实维护市场健康发展。 据悉，1月6日，英集芯在 上证e互动平台回复提问称 ，公司通过早期投资布局，已涉足脑机接口芯片 领域。英集芯表示， 公司推出的IPA1299是一款8通道、低噪声24位ADC芯片，专用于人体生物电信 号的高精度测量，可适用于脑电信号采集等脑机接口相关场景。IPA1299芯片已量产出货，性能参数 可媲美海外头部芯片产品。 当日晚间，上交所紧急向英集芯下发监管工作函，处理事由为关于深圳英集芯科技股份有限公司E互动 回复内容的监管工作函。 英集芯表示， 该产品 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yingjixin Technology Co., Ltd. for misleading statements related to information disclosure on January 6, 2026, regarding their brain-machine interface products [1]. Group 1: Incident Overview - On January 6, an investor inquired about the company's progress in brain signal acquisition technology. Yingjixin responded by highlighting their IPA1299 chip, which is designed for high-precision measurement of biological electrical signals and is suitable for brain-machine interface applications [2]. - Following this response, the Shanghai Stock Exchange issued a regulatory letter to Yingjixin regarding the content of their reply on the E-interaction platform [2]. Group 2: Product Details - On January 7, Yingjixin announced that the IPA1299 chip is an 8-channel, low-noise, 24-bit ADC primarily used for EEG, ECG, and EMG applications. It is designed for high-precision signal acquisition and is applicable in non-invasive brain-machine interface scenarios [3]. - The company noted that the IPA1299 is still in the market cultivation phase for non-invasive brain-machine interfaces and has not yet achieved significant sales or impacted the company's financial performance [3]. Group 3: Market Reaction - Despite the announcement clarifying the situation, Yingjixin's stock price opened over 9% higher on January 7, closing at 22.48 yuan per share, a 4.51% increase [4]. Group 4: Regulatory Actions - The Shanghai Stock Exchange's Sci-Tech Innovation Board issued a regulatory warning to Yingjixin and its then Secretary of the Board, Wu Renchao, for the misleading information [6].

Core Insights - The article highlights the increasing focus of institutional investors on hard technology breakthroughs and performance certainty for investment opportunities in 2026 [4] Group 1: Institutional Research Trends - In late 2025 to early 2026, institutions conducted research on approximately 1,162 companies, with a total of 30,000 receptions from listed companies across various core industries [3] - The shift in focus from merely gathering data to understanding practical applications indicates a significant change in investment strategies [9] Group 2: Brain-Computer Interface (BCI) Focus - Brain-computer interface technology has emerged as a key area of interest, with companies like Xiangyu Medical, Aipeng Medical, and Meihao Medical frequently hosting inquiries from fund managers [5][6] - Institutions are particularly interested in the depth of collaboration with innovative BCI clients and the feasibility of mass production [7][8] Group 3: AI Computing Power and Applications - The focus on artificial intelligence has shifted from foundational models to the iteration of computing power and practical applications [10] - Companies like Zhongji Xuchuang attracted attention for their 1.6T optical module orders and technology advancements, reflecting a market shift towards evaluating technological iteration speed [10] Group 4: Commercial Aerospace and Semiconductor Focus - Commercial aerospace has gained significant attention, with institutions exploring various segments such as rocket manufacturing and satellite components [17] - In the semiconductor sector, institutions are focused on overcoming technical barriers, with companies like Haimei Information and Huaren Micro receiving extensive inquiries regarding their advanced process products [22][23] - The trend of institutions closely monitoring companies with promising earnings forecasts indicates a more rational investment approach, seeking high-quality targets with core competitiveness [26]

Core Viewpoint - MiniMax has experienced a remarkable stock price surge since its debut on the Hong Kong stock market on January 9, reaching a market capitalization of over HKD 200 billion following the release of its new model M2.5, which has drawn significant attention and investment returns for its backers, particularly miHoYo, which has seen a substantial profit from its early investment [1][3][6]. Group 1: MiniMax's Performance and Market Response - MiniMax's stock price increased by over 13% on February 13, 2023, following the announcement of its new model M2.5, which is said to match the performance of Claude Opus 4.6 [1][2]. - The market responded quickly, with MiniMax's market capitalization exceeding HKD 200 billion [3]. - The company has achieved a unique position in the Chinese large model landscape, having gone from establishment to IPO in just four years [2]. Group 2: Investment and Returns - miHoYo, a gaming company, was one of the angel investors in MiniMax, investing at a post-money valuation of USD 200 million, and has since seen its investment return exceed 100 times [4][6]. - miHoYo's stake in MiniMax increased to 7.34% during subsequent funding rounds, and it currently holds approximately 5.24% of the company post-IPO, translating to a book value of nearly RMB 10 billion [5][6]. - Other notable investors in MiniMax include Hillhouse Capital, IDG Capital, Sequoia China, Alibaba, Tencent, and several others, indicating a broad and significant backing for the company [6]. Group 3: miHoYo's Financial Performance - miHoYo has disclosed that it has paid a total of RMB 15 billion in taxes from 2021 to 2025, reflecting its substantial revenue growth [11]. - In 2021, miHoYo reported a revenue of RMB 27.34 billion and a net profit of RMB 16.145 billion, with tax contributions increasing from RMB 1.8 billion in 2021 to a projected RMB 15 billion by 2025 [11][12]. - The company has made significant investments in various sectors, including technology and gaming, and has been actively involved in the IPO process of other companies [12][14].

Group 1 - The core viewpoint is that Qisheng Technology (603610) has gained market attention due to its stake in Mind Motion, which is venturing into the brain-computer interface (BCI) field with a new digital therapy product for sleep [1] - The launch of the BCI-based sleep therapy product aligns with China's recent breakthroughs in BCI space validation, potentially influencing market sentiment in the short term [1] - The company's main business includes smart home and sensor concepts, with a high proportion of overseas revenue benefiting from the depreciation of the RMB [1] Group 2 - In the past week, Qisheng Technology's stock price has experienced a volatile decline, with a drop of 1.91%, closing at 17.99 yuan [2] - The capital flow indicates a net outflow from major investors, with a net outflow of 5.8377 million yuan on February 13, indicating continuous reduction in holdings [2] - Technically, the stock price is approaching the lower support level of the Bollinger Bands at 17.18 yuan, necessitating attention to whether it can stabilize [2]

Core Viewpoint - The company, 美好医疗, has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1]. Group 1: Company Performance - 美好医疗's stock rose by 6.57% with a trading volume of 860 million yuan and a turnover rate of 6.75%, leading to a total market capitalization of 19.842 billion yuan [1]. - The company reported a revenue of 1.194 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.28%, while the net profit attributable to shareholders decreased by 19.25% [7][8]. - The company has a significant overseas revenue contribution, accounting for 86.64% of total revenue, benefiting from the depreciation of the yuan [3]. Group 2: Business Operations - 美好医疗 is engaged in the design, development, manufacturing, and sales of precision components and products in the medical device sector, with a focus on home respiratory machine components, cochlear implant components, and pulmonary function instruments [2][7]. - The company is actively collaborating with downstream brain-machine interface clients to facilitate efficient commercialization from laboratory research to mass production, although current revenue from this segment is still small [2]. - 美好医疗 has initiated the construction of automated production lines for weight loss pen orders, expected to be delivered next year [2]. Group 3: Market Dynamics - The company is categorized under the medical device sector, with its main products including home respiratory machine components (59.48% of revenue), consumer electronics components (14.61%), and other medical product components [7]. - The stock has shown signs of accumulation, with an average trading cost of 32.84 yuan, and is approaching a resistance level of 35.00 yuan, indicating potential for upward movement if this level is breached [6].

Group 1 - In January, the A-share market saw increased trading activity and risk appetite, with all three major indices achieving gains, notably the Shanghai Composite Index rising by 3.76% and the CSI 500 Index increasing by 12.12% [1] - The rise in cyclical industries such as precious metals, non-ferrous metals, chemicals, and oil and gas was driven by multiple factors including complex international dynamics, a weakening US dollar, and domestic industrial policy support, although there was significant volatility at the end of the month [1] - The technology sector, particularly AI applications, is expected to enter a critical validation window as large model technologies mature, with strong demand for computing power and investments in AI hardware like storage chips and semiconductor equipment [1] Group 2 - As of January 2026, the total number of bank wealth management products in the market reached 46,845, an increase of 553 from December 2025, with fixed-income products making up the majority at 43,215 [2] - In January, 2,969 new wealth management products were launched, a decrease of 305 from the previous month, with wealth management subsidiaries of banks accounting for 76.56% of the new issuances [2] - The overall risk level of wealth management products in January increased significantly, with 51 products rated as medium risk and 4 additional products rated as medium-high risk compared to the previous month [12] Group 3 - The asset allocation of wealth management products in January showed a high proportion of bonds and public funds, with a focus on cash, bank deposits, and short-term bond ETFs for liquidity and low risk [17] - Mixed wealth management products had diverse asset allocations, covering debt, convertible bonds, equity assets, and gold, with many products cautiously investing in gold ETFs to capture commodity investment opportunities [18] - The top five institutions accounted for 43.81% of the products listed, indicating a competitive advantage for state-owned and joint-stock bank wealth management subsidiaries [14]

Core Viewpoint - MiniMax has achieved a market capitalization exceeding 200 billion HKD since its listing on the Hong Kong stock exchange, driven by the launch of its new model M2.5, which has garnered significant market attention and investor returns [2][3]. Group 1: MiniMax's Market Performance - MiniMax's stock price surged over 13% on February 13, 2023, following the announcement of its M2.5 model, which is comparable to Claude Opus 4.6 in performance [3]. - The company reached a market valuation of over 200 billion HKD shortly after its IPO, marking a significant milestone in the tech industry [2][3]. Group 2: Investment Landscape - MiHoYo, a gaming company, was a key angel investor in MiniMax, investing at a post-money valuation of 200 million USD, and has seen its investment return exceed 100 times [4][5]. - Other notable investors in MiniMax include Hillhouse Capital, IDG Capital, Sequoia China, Alibaba, Tencent, and several others, indicating a strong backing from prominent venture capital firms [5]. Group 3: MiHoYo's Financial Contributions - MiHoYo has disclosed that it will contribute a total tax of 150 billion CNY over five years from 2021 to 2025, showcasing its significant financial impact [10][11]. - The company's tax contributions have increased from 1.8 billion CNY in 2021 to a projected 150 billion CNY by 2025, reflecting its rapid revenue growth [10]. Group 4: MiHoYo's Investment Strategy - MiHoYo has diversified its investment portfolio, backing various innovative projects, including brain-computer interfaces and private space ventures, indicating a forward-thinking investment approach [12][13]. - The company has positioned itself as a significant player in the venture capital space, actively engaging with young, tech-driven entrepreneurs [13].

联系人：李智 河南资本市场月报 分析师：李济生 登记编码：S0730522100002 lijs@ccnew.com 分析师：郑婷 登记编码：S0730524110001 zhengting@ccnew.com 相关报告 《河南资本市场月报（2026 年第 1 期）》 2026-1-15 《河南资本市场月报（2025 年第 11 期）》 2025-12-9 （2026 年第 2 期） 证券研究报告 发布日期：2026 年 2 月 13 日 投资要点： 风险提示：全球贸易和产业管制政策带来的不确定性风险；经济增长和 业绩不及预期；市场流动性风险。 本报告版权属于中原证券研究所股份有限公司 www.ccnew.com 请阅读最后一页各项声明 第 1页/共 20页 电话： 0371-65585629 地址： 郑州郑东新区商务外环路10号18楼 地址： 上海浦东新区世纪大道 1788 号 T1 座 22 楼 经济运行情况：2025 年，我国国内生产总值达到 1401879 亿元，比 上年增长 5.0%，经济增速目标圆满完成；2025 年河南省 GDP 达到 66632.79亿元，总规模位居全国第六、中部第一，GDP同 ...

Group 1 - Aihua Long faces regulatory scrutiny after being warned about its involvement in the brain-machine interface sector, leading to a formal investigation and losses in both its main business and stock trading activities [1] - Rongbai Technology's order value plummeted from 120 billion to a fine of 9.5 million due to false disclosures, with Chairman Bai Houshan fined 3 million [1] - BYD aims to sell 1.3 million vehicles overseas by 2026, contributing to China's export of over 7 million vehicles, marking a third consecutive year of global leadership in this sector [1] Group 2 - Haichang Intelligent has accounts receivable of 450 million, accounting for 56% of its revenue, and is involved in a patent lawsuit that may result in a compensation of 10.83 million [1] - Zhiji Motors has set a target of selling 81,000 vehicles by 2025 but has failed to meet its targets for three consecutive years, with CEO Liu Tao apologizing for safety concerns related to Tesla [1] - China Shenhua's restructuring plan, involving the acquisition of 12 companies, was approved in just six days, with a total value of 133.6 billion [1] Group 3 - Changchun High-tech anticipates a loss of 1 billion in the fourth quarter due to product price adjustments, while investing over 2 billion annually in R&D to reduce reliance on growth hormones [1] - Vanke's losses are expected to deepen, projecting a loss of 82 billion by 2025, with a bond extension of 6.8 billion and additional support of 2.36 billion from Shentie [1] - GAC Group has issued a rare profit warning, expecting losses between 8 billion to 9 billion, with CEO Feng Xingya reiterating the focus on three major battles for a turnaround [1] Group 4 - Nanhai Rural Commercial Bank was fined 3.8 million, with its net interest margin dropping to 1.15% after eight years of unsuccessful A-share market attempts [1] - Yuanji Food is closing one out of every three new stores, with Yuan Lianghong's wife holding shares in six supplier companies involved in related transactions worth 130 million [1] - "Cheese Queen" Chai Xiu has exited the market after costly marketing efforts, leading to a 70% drop in the stock price of Miaokelan Duo, with Mengniu taking full control [1] Group 5 - Zijin Mining has invested an additional 28 billion in overseas acquisitions, projecting a profit of 51 billion by 2025, with its market value stabilizing above 1 trillion [1] - Hunan Gold's restructuring of 2.7 billion in assets aims to increase resource reserves, benefiting from rising prices of antimony and tungsten, resulting in record profits exceeding 1.27 billion [1] - A shareholder named Yu Han was penalized over 1 billion for manipulating stock prices, while Doctor's Optical spent 50 million on traffic acquisition but only 3 million on R&D [1] Group 6 - SAIC-GM-Wuling's debt ratio has risen to 85.24%, despite a 20.5% increase in sales, which remains 53.5 thousand units below its peak [1]